France · Funded startup

Who invested in DOMAIN Therapeutics

7 rounds we have observed, with the 11 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Funding summaryUpdated 26 Oct 2026

$41Mraised across 7 rounds since 2002, from 7 sources

$2.6MSeries A$19MSeries B$10MSeries C$2.8MSeries D$2.5MVenture$230KGrant$3.9MRound
Latest round
Round, $3.9MMay 2019
Biggest round
$19MSeries B · May 2004
Step-upi
17×
Investors
11
See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

200220052008201120142017
$2.6MSeries A$19MSeries B$10MSeries C$2.8MSeries D$2.5MVenture$230KGrant$3.9MRound
First round
Series A, $2.6M
Feb 2002
Biggest round
$19M
Series B · May 2004
Usual gap between rounds
2.4 years
the median of 6

The rounds

  1. May 2019
    Round$3.9M1 returning

    Reported by FinSMEs

  2. Apr 2014
    Grant$230K1 new
    • The Michael J. Fox Foundation

    From a historical funding record

  3. Jul 2012
    Venture$2.5M2 new2 returning

    Reported by finsmes.com

  4. Dec 2008
    Series D$2.8M2 new

    From a historical funding record

  5. Oct 2006
  6. May 2004
  7. Feb 2002
    Series A$2.6M2 new

    From a historical funding record

Founders and team

From DOMAIN Therapeutics's own website: 9 on the team.

  • Sean A. MacDonaldChief Executive Officer
  • Marjorie SidhoumVice-President Business Development & Corporate Communication
  • Nathalie LenneVice-President Strategic Portfolio Management
  • Jean-Marie CuillerotChief Medical Officer
  • Stanislas-Léonard MalmezatChief Financial Officer
  • Stephan SchannChief Scientific Officer
  • Aurélie MaisnerDirector of Human Resources
  • Laurence RulleauChairwoman of the Board of Directors
  • Sylvie RyckebuschIndependant Director

Who was in which round

The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.

Series A2002Series B2004Series C2006Series D2008Venture2012Grant2014Round2019Auriga PartnersSofinnova PartnersBpifranceIdinvest PartnersSeventure PartnersEdmond de Rothschild Venture CapitalGroupe SiparexAIRFIAlsace créationSODIV ALSACE

Everyone who backed them

Auriga PartnersVC firm4rounds
Sofinnova PartnersVC firm3rounds
BpifranceGovernment2rounds
Idinvest PartnersPrivate equity2rounds
Seventure PartnersVC firm2rounds
Groupe SiparexVC firm2rounds
AIRFIInvestment firm2rounds
Alsace créationno record of our own yet1round
SODIV ALSACEno record of our own yet1round
The Michael J. Fox Foundationno record of our own yet1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

This firm lists DOMAIN Therapeutics as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.

3B Future Health Fund I & IIVC firmPer its own site

Quick answers about DOMAIN Therapeutics

Who invested in DOMAIN Therapeutics?

DOMAIN Therapeutics's investors include Auriga Partners, Sofinnova Partners, Bpifrance, Idinvest Partners and Seventure Partners, and 6 more on record.

How much has DOMAIN Therapeutics raised?

DOMAIN Therapeutics has raised $41M across 7 rounds since 2002.

When did DOMAIN Therapeutics last raise?

DOMAIN Therapeutics's most recent round was an Undisclosed round of $3.9M in May 2019.

What was DOMAIN Therapeutics's biggest round?

DOMAIN Therapeutics's largest round on record is $19M (Series B), in May 2004.

Who backed DOMAIN Therapeutics first?

DOMAIN Therapeutics's first round on record, in Feb 2002, was backed by Sofinnova Partners and Auriga Partners.

What stage is DOMAIN Therapeutics at?

DOMAIN Therapeutics's latest named round is an Undisclosed round, in May 2019.

Where is DOMAIN Therapeutics based?

DOMAIN Therapeutics is based in France.

Companies like DOMAIN Therapeutics

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.